Dapagliflozin

PreDiabetes

Centro Medico Nacional Siglo XXI IMSSSmall moleculePhase 2/3Dormant

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 89/ 100

Competitive context

46 Active assets in the PreDiabetes cohort.

Asset / Sponsor	Phase	Rating
Metformin Yu Chen	Phase 4	A
Liraglutide Woman's	Phase 4	BBB
Semaglutide Esbjerg Hospital - University Hospital of Southern Denmark	Phase 4	BBB
Exenatide RenJi Hospital	Phase 4	BBB
Semaglutide The University of Texas Health Science Center at San Antonio	Phase 4	BBB

View all 50 →

Same molecule, other indications

Dapagliflozin is also rated in:

type 2 diabetes mellitusDormant

BBB

Indicative ·

78 / 100

metabolic dysfunction-associated steatotic liver diseaseDormant

BBB

Indicative ·

77 / 100

arteriosclerosis disorderDormant

BBB

Indicative ·

73 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.